|
EP3662898A1
|
|
Solid composition comprising mesalazine
|
|
EP3662901A1
|
|
Delayed release drug formulation comprising an outerlayer with an enzymaticyaaly degradable polymer, its composition and its method of manufacturing
|
|
EP3662895A1
|
|
A process for manufacturing reducing sugar-free 5-asa tablet cores
|
|
EP3662900A1
|
|
Colonic drug delivery formulation
|
|
EP3662902A1
|
|
Colonic drug delivery formulation
|
|
WO2020114616A1
|
|
Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
|
|
EP3459527A1
|
|
Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
|
|
EP3459528A1
|
|
Preparation of solid dosage forms comprising antibodies by solution/suspension layering
|
|
EP3459529A1
|
|
Preparation of sustained release solid dosage forms comprising antibodies by spray drying
|
|
EP3456738A1
|
|
Antibody variants
|
|
EP3456737A1
|
|
Antibody variants
|
|
EP3456736A1
|
|
Antibody variants
|
|
EP3456739A1
|
|
Use of anti-tnfalpha antibodies for treating wounds
|
|
EP3409688A1
|
|
Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof
|
|
EP3257501A1
|
|
Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating
|
|
EP3219726A1
|
|
Anti-tnf alpha-antibodies and functional fragments thereof
|
|
RS61412B1
|
|
Anti-tnf alpha-antibodies and functional fragments thereof
|
|
MX2019002162A
|
|
Formulation of a drug for delayed-release.
|
|
EP3078366A1
|
|
Microgel particles
|
|
NZ720512A
|
|
Multi-particulate drug delivery system
|
